Lex Kogan, Ibogaine Developer, Celebrates Recent CDC Panel
Lex Kogan, Ibogaine developer, has spoken out in support of a recent CDC question-and-answer session.
NEW YORK, May 27, 2013 /PRNewswire-iReach/ -- Recently PBS hosted a question-and-answer session in which viewers were able to submit inquiries, on the topic of prescription drug addiction, to members of the Center for Disease Control; the Q&A has won the attention, and the praise, of Lex Kogan, Ibogaine developer and drug recovery advocate. Through his pioneering Ibogaine program, Kogan has helped numerous individuals recover from their addictions to Oxycontin and other narcotics. Now, he has released a statement to the press, highlighting the PBS initiative.
"Education is the silver bullet, the important first step toward eliminating drug addiction," says Lex Kogan, in his press statement. "As such, this PBS program is to be commended. It does an excellent job of dispensing some important information about prescription drug addictions, and about the recovery process."
The first question in the program is about how doctors can overprescribe medicines when state regulations have prescription limits in place. While 35 states had legal limits in place by 2010, the CDC answers, there are may complexities to these regulations. In many states, "such laws are restricted to certain schedules of drugs, to emergency prescriptions or to members of certain benefit plans (such as Medicaid)." Continues the CDC, "Very few states have laws requiring specific steps when exceeding daily dosage limits for all prescription painkillers." The result is that these legal limitations really do very little to curb overprescribing.
The CDC panel also addresses the question of whether doctors receive incentives when patients fill certain prescriptions—particularly those for opioids. The short answer is that no, generally speaking, they do not, but there are related factors in play, such as insufficient insurance coverage for things like physical and behavioral therapies. Says the CDC, it is important to weigh the "potential incentives for prescribing decisions, like insurance coverage of certain drugs or inadequate coverage for physical or behavioral therapy."
A parent, meanwhile, asks the CDC where to send a child for treatment. The CDC says that it does not recommend specific facilities, but it does espouse the value of programs like the Substance Abuse and Mental Health Services Administration, which does seek to put individuals in contact with treatment facilities.
One final question is that of how many prescription drug addicts are also addicted to drugs like marijuana—and the answer is surprisingly few. "In 2010, marijuana was involved in less than 1 percent of prescription painkiller overdose deaths," the CDC informs.
"All of these questions and answers lead one to believe that, in many ways, our medical system leaves itself wide open for drug abuse cases—and yet the fact that the CDC does so much to educate is truly impactful," says Lex Kogan. "Ibogaine is the only other thing that I would mention; there are few better options for safe liberation from opiate addiction."
According to Lex Kogan, Ibogaine is an advanced form of drug detox and rehabilitation; Kogan pioneered this treatment approach.
Lex Kogan, Ibogaine pioneer, is passionate about delivering safe and healthy detox options and rehabilitation services to those caught in the throes of drug addiction, particularly to opiates such as Oxycontin. A student of drug rehabilitation methodologies since 2001, Kogan played an instrumental role in bringing the Ibogaine Treatment approach to America. Kogan continues to use advanced medical methodologies to help individuals end the vicious cycle of addiction.
Media Contact: Martin Ackerman, mark-pr.com, (678) 685-8304, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Lex Kogan
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.